True, I forgot about the embargo reason, but I think they had some data on the first subset even before they submitted an abstract for acceptance. If they had seen many instances of tumor regression and necrosis like that which was just reported in the case study (prior to their abstract submission), I think they would have shouted it. Still, it makes more sense to wait for the second set of data to report anything at all, but I think they want to have some data for ASCO and the public. Does that mean I have no appreciation for how difficult it is to treat lung cancer?
Market Data 
Markets 
AI
